FULC
Fulcrum Therapeutics, Inc. NASDAQ Listed Jul 18, 2019$6.87
Pre-mkt
$7.09
+3.05%
Mkt Cap $371.7M
52w Low $4.91
18.1% of range
52w High $15.74
50d MA $7.63
200d MA $8.83
P/E (TTM)
-6.2x
EV/EBITDA
-7.2x
P/B
1.3x
Debt/Equity
0.0x
ROE
-22.8%
P/FCF
-11.9x
RSI (14)
—
ATR (14)
—
Beta
3.27
50d MA
$7.63
200d MA
$8.83
Avg Volume
1.1M
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
26 Landsdowne Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | TNS | -0.31 | -0.25 | +19.4% | 7.72 | +0.0% | -3.6% | -7.4% | -7.6% | -4.7% | -9.1% | — |
| Feb 24, 2026 | TNS | -0.31 | -0.31 | +0.0% | 8.58 | -2.6% | +4.7% | +1.7% | -2.3% | -9.0% | -8.3% | — |
| Oct 29, 2025 | TNS | -0.29 | -0.31 | -6.9% | 9.36 | +1.6% | -8.1% | -6.5% | -3.6% | -10.6% | -15.9% | — |
| Jul 29, 2025 | TNS | -0.29 | -0.28 | +3.4% | 7.59 | +0.1% | -9.1% | -11.3% | -10.0% | -8.3% | -9.4% | — |
| May 1, 2025 | TNS | -0.29 | -0.28 | +3.4% | 4.38 | +0.7% | +28.3% | +30.8% | +22.1% | +15.8% | +23.5% | — |
| Feb 25, 2025 | TNS | -0.28 | -0.31 | -10.7% | 3.70 | -0.8% | -10.3% | -8.9% | -3.0% | -12.4% | -11.6% | — |
| Nov 13, 2024 | TNS | -0.40 | -0.35 | +12.5% | 3.56 | +0.3% | -6.7% | -15.4% | -14.9% | -15.4% | -16.0% | — |
| Jul 31, 2024 | TNS | 0.01 | 0.87 | +7060.9% | 9.28 | +1.5% | -2.9% | +2.9% | -8.8% | -4.4% | -10.7% | — |
| May 13, 2024 | TNS | -0.44 | -0.43 | +2.3% | 7.35 | +7.2% | +7.6% | +12.2% | +6.1% | +2.7% | +4.8% | — |
| Feb 27, 2024 | TNS | -0.44 | -0.40 | +9.1% | 10.18 | +0.9% | +1.4% | +0.3% | +8.0% | +11.3% | +7.7% | — |
| Nov 7, 2023 | TNS | -0.44 | -0.39 | +11.4% | 4.29 | -0.2% | -2.8% | -21.0% | -18.4% | -19.1% | -8.4% | — |
| Aug 3, 2023 | TNS | -0.44 | -0.38 | +13.6% | 3.85 | +0.3% | +2.6% | +4.2% | +4.7% | +3.1% | +11.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 11 | Truist | Maintains | Buy → Buy | — | $13.80 | $13.55 | -1.8% | -7.2% | -5.8% | -6.4% | -9.4% | -12.5% |
| Dec 9 | BofA Securities | Maintains | Underperform → Underperform | — | $12.99 | $12.72 | -2.1% | +12.4% | +6.2% | -1.5% | +0.1% | -0.5% |
| Dec 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.90 | $12.96 | +45.6% | +46.0% | +64.0% | +55.1% | +43.8% | +46.1% |
| Dec 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.90 | $12.96 | +45.6% | +46.0% | +64.0% | +55.1% | +43.8% | +46.1% |
| Dec 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.90 | $12.96 | +45.6% | +46.0% | +64.0% | +55.1% | +43.8% | +46.1% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.90 | $12.96 | +45.6% | +46.0% | +64.0% | +55.1% | +43.8% | +46.1% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.29 | $11.73 | +3.9% | +4.0% | +2.2% | +0.3% | -3.1% | -12.6% |
| Oct 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.36 | $9.51 | +1.6% | -8.1% | -6.5% | -3.6% | -10.6% | -15.9% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.36 | $9.51 | +1.6% | -8.1% | -6.5% | -3.6% | -10.6% | -15.9% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.99 | $9.12 | +1.4% | +2.6% | +7.9% | +0.6% | -0.4% | +2.6% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.59 | $7.60 | +0.1% | -9.1% | -11.3% | -10.0% | -8.3% | -9.4% |
| Jul 29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $7.81 | $7.66 | -1.9% | -2.8% | -11.7% | -13.8% | -12.5% | -10.9% |
| May 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.90 | $7.11 | +3.0% | +2.5% | -0.3% | +0.9% | +2.0% | +1.9% |
| May 23 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $6.12 | $6.82 | +11.4% | +5.2% | +3.8% | +12.7% | +15.5% | +12.4% |
| May 15 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $5.63 | $5.99 | +6.4% | +17.2% | +22.2% | +23.1% | +15.6% | +11.0% |
| Feb 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.70 | $3.67 | -0.8% | -10.3% | -8.9% | -3.0% | -12.4% | -11.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.56 | $3.57 | +0.3% | -6.7% | -15.4% | -14.9% | -15.4% | -16.0% |
| Nov 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $3.56 | $3.57 | +0.3% | -6.7% | -15.4% | -14.9% | -15.4% | -16.0% |
| Sep 13 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.44 | $3.44 | +0.0% | -7.6% | -7.6% | +1.5% | +0.0% | +0.3% |
| Sep 13 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $3.44 | $3.44 | +0.0% | -7.6% | -7.6% | +1.5% | +0.0% | +0.3% |
| Sep 12 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $8.85 | $2.94 | -66.8% | -61.1% | -64.1% | -64.1% | -60.6% | -61.1% |
| Sep 12 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $8.85 | $2.94 | -66.8% | -61.1% | -64.1% | -64.1% | -60.6% | -61.1% |
| Sep 12 | Stifel | Downgrade | Buy → Hold | — | $8.85 | $2.94 | -66.8% | -61.1% | -64.1% | -64.1% | -60.6% | -61.1% |
| Sep 12 | BofA Securities | Downgrade | Neutral → Underperform | — | $8.85 | $2.94 | -66.8% | -61.1% | -64.1% | -64.1% | -60.6% | -61.1% |
| Sep 9 | BofA Securities | Upgrade | Underperform → Neutral | — | $8.54 | $8.90 | +4.2% | +1.1% | -1.3% | +3.6% | -59.7% | -62.8% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.28 | $9.42 | +1.5% | -2.9% | +2.9% | -8.8% | -4.4% | -10.7% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.53 | $6.58 | +0.8% | +8.6% | +19.4% | +22.7% | +29.4% | +32.6% |
| May 14 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.35 | $7.88 | +7.2% | +7.6% | +12.2% | +6.1% | +2.7% | +4.8% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.35 | $7.88 | +7.2% | +7.6% | +12.2% | +6.1% | +2.7% | +4.8% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.35 | $7.88 | +7.2% | +7.6% | +12.2% | +6.1% | +2.7% | +4.8% |
| May 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.47 | $8.35 | +11.8% | -1.6% | +5.9% | +10.4% | +4.4% | +1.1% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.18 | $10.27 | +0.9% | +1.4% | +0.3% | +8.0% | +11.3% | +7.7% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.18 | $10.27 | +0.9% | +1.4% | +0.3% | +8.0% | +11.3% | +7.7% |
| Jan 26 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.00 | $7.04 | +0.6% | -0.7% | +7.0% | +3.4% | +3.1% | +14.6% |
| Jan 25 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.70 | $6.80 | +1.5% | +4.5% | +3.7% | +11.8% | +8.1% | +7.8% |
| Aug 23 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.43 | $5.60 | +3.1% | +12.0% | -0.4% | +1.3% | +6.4% | +2.9% |
| Aug 22 | Stifel | Upgrade | Hold → Buy | — | $3.92 | $5.28 | +34.7% | +38.5% | +55.1% | +38.0% | +40.3% | +47.4% |
| Aug 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.92 | $5.28 | +34.7% | +38.5% | +55.1% | +38.0% | +40.3% | +47.4% |
| Aug 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.85 | $3.86 | +0.3% | +2.6% | +4.2% | +4.7% | +3.1% | +11.2% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.64 | $3.62 | -0.5% | +4.4% | +0.5% | -9.9% | -10.7% | -15.7% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.64 | $3.62 | -0.5% | +4.4% | +0.5% | -9.9% | -10.7% | -15.7% |
| May 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.74 | $2.80 | +2.2% | +3.6% | +12.4% | +19.3% | +19.3% | +16.1% |
| May 4 | Goldman Sachs | Downgrade | Buy → Neutral | — | $2.93 | $2.70 | -7.8% | -6.5% | -3.1% | +5.1% | +11.6% | +11.6% |
| Mar 13 | Goldman Sachs | Maintains | Buy → Buy | — | $4.51 | $4.43 | -1.8% | -0.2% | -12.0% | -15.7% | -18.4% | -23.5% |
| Mar 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.82 | $4.56 | -5.4% | -6.4% | -6.6% | -17.6% | -21.2% | -23.7% |
| Mar 10 | Credit Suisse | Downgrade | Outperform → Neutral | — | $4.82 | $4.56 | -5.4% | -6.4% | -6.6% | -17.6% | -21.2% | -23.7% |
| Mar 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.82 | $4.56 | -5.4% | -6.4% | -6.6% | -17.6% | -21.2% | -23.7% |
| Feb 28 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $5.80 | $5.32 | -8.3% | +4.1% | +8.4% | +4.3% | +3.3% | +2.9% |
| Feb 27 | Credit Suisse | Maintains | Outperform → Outperform | — | $5.66 | $5.77 | +1.9% | +2.5% | +6.7% | +11.1% | +6.9% | +5.8% |
| Feb 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.66 | $5.77 | +1.9% | +2.5% | +6.7% | +11.1% | +6.9% | +5.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Fulcrum Therapeutics, Inc. -- 8-K 5.02: Executive Change
Fulcrum Therapeutics appointed Josh Lehrer to its board as a Class III director, potentially signaling fresh strategic input and expanded governance oversight for the therapeutic company.
Apr 27
8-K
Fulcrum Therapeutics, Inc. -- 8-K Filing
Fulcrum Therapeutics reported positive 12-week PIONEER trial data for pociredir in its 20 mg cohort, supporting the drug candidate's potential in treating genetically defined rare diseases.
Feb 24
Data updated apr 25, 2026 10:22am
· Source: massive.com